Translational Relevance
This phase I study investigates the tolerability and clinical impact of an agonist CD40 monoclonal antibody (CP-870,893) when administered in combination with gemcitabine for the treatment of patients with chemotherapy-naive advanced pancreatic ductal adenocarcinoma. We show that combination of CP-870,893 with gemcitabine is well tolerated and associated with preliminary evidence of efficacy. Treatment produced a systemic immune response that was marked by leukocyte trafficking, cytokine production and cellular activation. Using novel analyses of metabolic imaging, we observed in many patients a cumulative decrease with each cycle of therapy in the metabolic activity of the primary pancreatic lesion. However, treatment responses of metastatic lesions were heterogeneous. These findings highlight the biological heterogeneity of pancreatic carcinoma and demonstrate a role for metabolic imaging in understanding treatment responses.
Introduction
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer death in the United States and is notoriously resistant to conventional forms of treatment including chemotherapy and radiation therapy (1, 2) . This finding may be related to emerging data demonstrating the importance of the tumor microenvironment in regulating therapeutic efficacy (3) (4) (5) (6) . In PDA, the tumor microenvironment is marked by poor vascularity, dense desmoplasia, and a leukocyte reaction dominated by macrophages (3, 7, 8) . Strategies that target this desmoplastic reaction may be critical for improving therapeutic efficacy in PDA (3, 5) .
Tumor-associated macrophages, among other hematopoietic and non-hematopoietic cells, can express the cell surface molecule CD40, a member of the tumor necrosis factor (TNF) receptor superfamily (9). CD40 is a major determinant in the development of T cell dependent anti-tumor immunity through its ability to "license" antigen-presenting cells for tumor-specific T cell priming and activation (10) (11) (12) (13) (14) (15) . In a preclinical model of PDA, we reported that systemic CD40 activation can also induce tumor regression that is independent of T cells, but requires macrophages that rapidly infiltrate tumor lesions, become tumoricidal, and attack the tumor microenvironment by facilitating stromal depletion (16) .
CP-870,893 is a fully human and selective CD40 agonist monoclonal antibody (mAb) that as a single agent has demonstrated promising clinical activity, particularly in patients with melanoma (17). Because preclinical data suggest that chemotherapy can synergize with CD40 agonists, we conducted a phase I study using CP-870,893 in combination with gemcitabine and observed major tumor regressions in some patients with advanced PDA (16) 
Pharmacodynamic Studies
Serum and peripheral blood for assessment of cytokines and B lymphocyte activation were obtained at baseline and at defined times during cycle 1 after infusion of gemcitabine and CP-870,893. Serum cytokine levels of IL-6, IL-8, and IL-10 were determined by enzyme-linked 
Tumor Response
All patients who received at least one dose of CP-870,893 were evaluated for toxicity and efficacy. Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline and every 8 weeks according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.
PET Data Acquisition and Analysis
Metabolic activity was assessed in patients enrolled in the MTD expansion cohort by and then every 8 weeks while on treatment. FDG-PET/CT was performed after patients had fasted for >6 hours and plasma glucose levels were determined to be <200 mg/dl. Approximately 15 mCi of FDG were administered intravenously, and images were acquired ~60 minutes later from skull base to mid thighs. Analysis was performed using the ROVER software package (ABX, GmbH, Germany), providing a semi-automated approach to delineate FDG avid lesions and to estimate metabolically active volume (MAV) and mean standardized uptake value (SUV mean ) for individual lesions from PET datasets as previously described (22 
Statistical Analysis
Statistical analyses were performed using Stata 10.0 for Windows (StataCorp, College Station Texas, USA). PFS was defined as time from start of study treatment to disease progression or patient death, whichever occurred first. OS was defined as time from start of study treatment to patient's death. PFS and OS were analyzed using Kaplan-Meier methods. The Spearman rank test was used to estimate correlations between changes in biomarkers relative to baseline and OS. For analysis of change from baseline of pharmacodynamic end points, a repeated measures analysis of variance (ANOVA) was performed. All analyses were carried out per protocol on patients receiving at least one dose of CP-870,893.
Results

Patient Characteristics
Twenty-two patients with advanced chemotherapy-naïve PDA were enrolled (Table 1) 
Treatment Exposure
The median number of cycles administered was 4 (range, 1 to 12). Gemcitabine dose was reduced by 25% for thrombocytopenia or neutropenia and was required in 55% of patients with a median of 1 dose reduction (range, 0 to 5) per patient. No dose reductions in CP-870,893 were required. Discontinuation of therapy was due to progressive disease (n=14, 66%), unacceptable toxicity without progressive disease (n=1, 5%), patient discretion (n = 4, 19%), or AE (n = 2, 10%).
Immune modulation
Rapid decreases in absolute monocyte count (AMC) and absolute lymphocyte count (ALC) were observed in peripheral blood one day after gemcitabine administration ( Supplementary Fig S1A) . Further decreases in AMC and ALC were observed after CP-870,893 infusion with a nadir on day 4. Both AMC and ALC recovered by day 8 to near baseline levels.
Decreases in ALC were associated with a rapid decline in absolute levels of CD19 Fig S1C) . These findings are consistent with preclinical data demonstrating that CD40 agonists induce immune activation and trafficking of leukocytes to lymphoid organs (16) . No relationship was found between peak cytokine levels and development or grade of CRS.
FDG-PET Response
Ten patients in the MTD expansion cohort were evaluated using European Organization for Research and Treatment of Cancer (EORTC) criteria for partial metabolic response (PMR; >25% reduction in SUVmax) detected by FDG-PET/CT (23). Eight of 10 patients completed at least two cycles of therapy, and two achieved a PMR. To further quantify metabolic responses, we determined the percentage reduction in the sum of SUV max for up to five predefined lesions (up to 2 per organ) with the most intense FDG uptake (24) . On average, the sum of SUV max was reduced by 29% in target lesions after two cycles of therapy with 6 of 8 patients achieving >25% reduction.
Because preclinical data demonstrate the capacity of CD40 agonists to target the microenvironment of primary pancreatic tumors (16), we examined metabolic responses specifically within the primary lesion. After two cycles of therapy, an average reduction of 26.9% in SUV max was observed in pancreatic lesions, and all patients showed some reduction. To quantify this metabolic response, changes in primary tumor MVP mean were determined. A decrease in MVP mean was observed in 6 of 8 patients after two cycles of therapy with changes seen as early as day 15 (Fig 2A and 2B) . Further reductions in MVP mean were also observed with subsequent cycles of therapy. However, after six cycles of therapy, three patients, despite
Research. achieving >50% reduction in MVP mean of the primary lesion, were withdrawn from study due to progressive disease of metastatic lesions. This suggested heterogeneity of the tumor response to therapy, which prompted investigation of metastatic lesions.
The most common metastatic site in this study was the liver (Table 1) . For this reason, we evaluated the impact of therapy on metabolic responses of hepatic lesions only. Eight of 10 patients had hepatic lesions; 6 of whom completed at least two cycles of therapy. Four patients achieved a >25% reduction in total hepatic lesion MVP mean ; this metabolic response, though, was sometimes transient (Fig 2C) . Moreover, metabolic changes in hepatic lesions were found to be heterogeneous ( Fig 2D) . For patient 10031016, a marked metabolic response was observed in both the primary and hepatic lesions (Fig 2) . After four cycles of therapy, we biopsied the responding hepatic lesion. We previously reported histological analysis of this lesion which demonstrated an impressive immune infiltrate that was dominated by macrophages with an absence of viable tumor cells (16) . Thus, a metabolic response correlated with a pathological response for this patient. To understand the heterogeneity of metabolic responses observed with treatment, we quantified responses of all identifiable lesions after 2 cycles of therapy (Fig 3A) .
This analysis revealed that metabolic responses within individual patients varied considerably from complete metabolic response to progression, sometimes with development of new lesions.
This treatment response heterogeneity was particularly pronounced in the liver (Fig 3B) . Overall, these data demonstrate that FDG-PET/CT based treatment responses were heterogeneous in many patients.
Efficacy, Pharmacodynamic and Immunologic Correlative Results
Research. 
Survival. Median PFS was 5.2 months (95% CI, 1.9 to 7.4 months); median OS was 8.4 months (95% CI, 5.3 to 11.8 months); and 1-year OS was 28.6% (Fig 4A) .
Response Rate. Overall response rate (ORR) based on RECIST 1.0 was 19% with four patients achieving a PR. Stable disease was seen in 11 patients. In addition, one patient withdrawn after one dose of CP-870,893 due to DLT restarted gemcitabine alone and achieved a PR off-study, as previously reported (16) .
Correlative Studies. Exploratory analyses were performed to correlate changes in immune activation, tumor biomarkers, tumor response and metabolic response with OS.
Treatment-related increases in cytokine levels (i.e. IL-6, IL-8, and IL-10) during cycle 1 were not associated with OS (Supplementary Table S1 ). CA19-9 levels were available for 12 patients with 9 patients demonstrating decreases after cycle 1 that correlated with improved OS (Fig 4B) .
Response rate determined by RECIST 1.0 after cycle 2 was also associated with improved OS (Fig 4C) . In contrast, metabolic responses using EORTC criteria or by evaluating SUV max for up to five predefined lesions did not correlate with OS (Supplementary Table S1 ).
Because metabolic responses to therapy were heterogeneous, we examined the association between OS and changes in metabolic activity observed within the liver and pancreas separately. Changes in total MVP mean as well as SUV max and MVP mean of primary pancreatic lesions were not associated with OS. In contrast, a decrease in total hepatic lesion MVP mean after cycle 2 was associated with improved OS (Supplementary Table S1 ). Furthermore, analysis of 7 patients with hepatic lesions who underwent FDG-PET/CT after two weeks of therapy revealed a decrease in total hepatic lesion MVP mean at this early time point that was also strongly correlated with OS (Fig 4D) . Patients with a metabolic response in the liver at two weeks also achieved a PR by RECIST 1.0. Strategies that target the stromal microenvironment may improve outcomes for patients with PDA. Preclinical studies have suggested that the mechanism of action of CP-870,893 when used in PDA is dependent on peripheral blood monocytes which are induced to rapidly leave circulation, infiltrate tumor lesions, and orchestrate degradation of the stromal microenvironment (16) . Consistent with this, we observed a rapid decrease in monocyte levels in patients after CP-870,893 infusion; however, because gemcitabine also produced a decrease in peripheral blood monocytes, we speculate that the full anti-tumor activity of an agonist CD40 antibody in patients may have been hindered in the current study by myelosuppression from repeated administration of gemcitabine. In this regard, because agonist CD40 antibodies can rapidly deplete the stroma that is a critical barrier to drug delivery, we propose that chemotherapy administration after, rather than before, the infusion of CD40 agonists would represent a novel approach to enhance efficacy while eliminating potential deleterious effects of chemotherapy on CP-870,893 activity.
Moreover, this treatment schedule would permit the use of functional imaging approaches such as FDG-PET/CT performed one day after administration of CP-870,893 to investigate the impact of delivering an agonist CD40 antibody on the biology of primary and metastatic tumor lesions.
To understand the impact of therapy on tumor-associated stroma, tissue biopsies could also be performed before and after delivery of CP-870,893 or alternatively, CP-870,893 could be administered to patients with resectable PDA in the neoadjuvant setting prior to surgical resection. It is expected that these study approaches would provide further insight into the biological impact of CP-870,893 on PDA tumor biology. To understand the impact of therapy on tumor biology, we incorporated FDG-PET/CT imaging into this study. FDG-PET/CT has been used to assess responses to chemotherapies and targeted therapies in various solid malignancies including PDA (5, 26, 27) . However, its utility in predicting responsiveness to immunotherapy in solid malignancies has not been well explored. 
finding may reflect the small sample size of this study. However, consistent with the heterogeneity in metabolic responses that we observed between primary and metastatic lesions, we found that changes in hepatic lesion MVP mean determined by FDG-PET/CT strongly correlated with OS. While decreases in primary lesion MVP mean were not statistically significant, a trend toward improved overall survival was observed and may have been appreciated with a larger sample size.
Metabolic responses were commonly seen within primary lesions with each cycle of therapy. However, the metabolic response of hepatic lesions was heterogeneous with some lesions showing no response to therapy, even in patients where other lesions responded with complete loss of metabolic activity. This disparity in response observed between primary and metastatic lesions can be observed by FDG-PET imaging in some patients receiving standard chemotherapy alone (28) (29) (30) . Here, we have used FDG-PET/CT imaging to demonstrate and quantify heterogeneity in metabolic responses observed with therapy in PDA. While the role of CP-870,893 in contributing to response heterogeneity seen between primary and metastatic lesions cannot be determined from our analyses, the disparate responses observed suggest differences in tumor biology such that metastasis biology may be a unique and major site of resistance for both chemotherapy and immunotherapy based approaches.
Although the results from this Phase I study are encouraging, our sample size was small and thus, we are unable to determine the clinical benefit achieved with adding CP-870,893 to gemcitabine chemotherapy. As a result, further investigation with randomized clinical studies will be necessary to determine a role for CP-870,893 in the treatment of PDA. Nonetheless, our study suggests the value of incorporating early FDG-PET/CT imaging to evaluate benefit from therapeutic approaches in PDA and for understanding heterogeneity in treatment responses.
